Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7A8TW)

• Drug Name: Ezetimibe Drug Info
• Synonyms: Ezedoc; Ezetimib; Ezetrol; Zetia; Zient; Essex brand of ezetimibe; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH58235; Sch 58235; Ezetimibe [USAN:INN]; Inegy (TN); MK-0653; SCH-58235; Schering-Plough brand of ezetimibe; Vytorin (TN); Zetia (TN); Zetia , Ezetrol, Ezetimibe; Ezetimibe (JAN/USAN/INN); (-)-Sch 58235; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one; (3R,4S)-1-(p-Fluorophenyl)-3-((3S)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-(4-hydroxyphenyl)-2-azetidione; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone
• Therapeutic Class: Anticholesteremic Agents
• Cross-matching ID:
  PubChem CID: 150311
  ChEBI ID: CHEMBL49040
  CAS Number: CAS 163222-33-1
  TTD Drug ID: D09LWS
  VARIDT Drug ID: DR00140
  INTEDE Drug ID: DR0677
  ACDINA Drug ID: D00262

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.30	0.00e+0	19/20 (95%)	MSMO1;CYP51A1;DHCR24;...
Terpenoid backbone biosynthesis	2.03	0.00e+0	18/22 (81.82%)	HMGCS1;HMGCR;IDI1;...
PPAR signaling pathway	1.98	0.00e+0	66/74 (89.19%)	SCD;HMGCS1;PCK2;...
Synthesis and degradation of ketone bodies	1.82	2.98e-2	9/10 (90%)	HMGCS1;BDH2;ACAT2;...
Biosynthesis of unsaturated fatty acids	1.77	4.17e-2	21/27 (77.78%)	SCD;FADS2;FADS1;...
Proteasome	-1.74	4.96e-2	44/46 (95.65%)	PSME4;PSME1;PSMD1;...
Fc gamma R-mediated phagocytosis	-1.77	4.50e-2	79/97 (81.44%)	FCGR3B;RAC2;ARPC1A;...
Parkinson disease	-1.86	2.25e-2	176/249 (70.68%)	PSMD3;NDUFA3;NDUFA9;...
Collecting duct acid secretion	-1.96	8.58e-3	22/27 (81.48%)	ATP6V1B2;ATP6V1F;ATP6V0A4;...
Huntington disease	-2.03	6.44e-3	233/306 (76.14%)	PSMD3;NDUFA3;AP2M1;...
Oxidative phosphorylation	-2.16	0.00e+0	93/133 (69.92%)	NDUFB5;NDUFS4;NDUFA7;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼